Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Pinder is a medical oncologist and specialist in lung cancer and mesothelioma at the renowned H. Lee Moffitt Cancer Center in Tampa, where she is an Assistant Member, involved with direct patient care and clinical research. After training at Stanford for medical school, Dr. Pinder did her internship and residency in general medicine at the University of North Carolina at Chapel Hill. She then completed her oncology fellowship specialty training at the MD Anderson Cancer Center in Houston.

Like Gleevec for Lung Cancer: A Novel Treatment for EML4-ALK Lung Cancer
Please Note: New Treatments Have Emerged Since this Original Post
Mary Pinder, MD, GRACE Faculty

Please Note: New Treatments Have Emerged Since this Original Post

Everyone is now familiar with the success stories of targeted agents in cancer therapy. A new promising targeted agent is Pfizer drug PF02341066, the story of which may be more analogous to the development of Gleevec (imatinib)or Herceptin (trastuzumab) than to Tarceva Tarceva. Both of the former drugs were tested in selected patients, with the idea that we knew which patients were likely to benefit. This is in contrast to Tarceva, which was tested in unselected patients and found to benefit a subset; it was only afterwards that investigators identified the critical importance of EGFR mutations. At the recent ASCO meeting, Dr. Eunice Kwak presented fascinating results of a trial in which a novel agent was tested in patients selected because of a known genetic abnormality in their lung cancers. To provide a little background, the EML4-ALK fusion gene was identified in 2007 by a group of Japanese investigators headed by Dr. Hiroyuki Mano, who identifed a novel fusion gene from a surgical specimen of a patient with lung adenocarcinoma. The EML4 gene and the ALK gene, which are normally separate from each other but both on chromosome 2, had become fused together in this patient's cancer. This fusion results in increased activity of ALK, which was already known to be implicated in a certain type of lymphoma. The authors subsequently found that this fusion gene was present in the tumors of other patients. When they put this gene into cells and then put the cells into mice, the mice developed tumors. In the lab, they tested an inhibitor of ALK against cancer cells with this fusion gene and found that it dramatically inhibited their growth. Subsequent studies have identified that patients with the EML4-ALK fusion gene tend to be younger than the average lung cancer patient, are more likely to be light or never smokers, and have adenocarcinomas. While these clinical characteristics are also shared by patients with EGFR mutations, patients with EML4-ALK do not have EGFR mutations.

In another ASCO 2009 abstract, Dr. Alice Shaw and colleagues performed a retrospective study of the frequency of EML4-ALK in patients with these clinical characteristics. They found that 13% of the 141 patients in their sample had this fusion gene. The patients with the fusion gene were younger (average age 52 vs. 64 in those who didn't have the mutation) and were more likely to be male. None of the patients with EML4-ALK had responded to treatment with Tarceva or Iressa. However, patients with EML4-ALK were just as likely to respond to chemotherapy and their 1-year survival was similar to other patients in the group. In the presentation referenced above, Dr. Kwak and colleagues initially conducted a first-in-human study to determine the maximum tolerated dose of the drug. One patient in that initial group (a 49-year-old man) had an EML4-ALK lung cancer. He had a dramatic response to treatment, coming off oxygen after receiving the drug. The side effects of the drug overall were overall mild: nausea, fatigue and liver enzyme elevations the most common. The next phase of the study included only patients with ALK fusions. Out of 19 patients, over 50% had a response to treatment and 80% had either a response or stable disease. These results are especially impressive given that most of the patients had received numerous previous treatments for their lung cancers. On the basis of these promising results, a large phase III study of PF02341066 is planned to further evaluate this drug for patients with EML4-ALK lung cancer. The story of EML4-ALK lung cancer is a new and important one, and it gives us a glimpse into a future where the idea of treating all patients with NSCLC the same way will be preposterous. This all started with an analysis of a single patient's tumor and is one of the most elegant examples of translational research and personalized medicine that I have seen: a discovery going from a patient to the lab and back to patients, all within the space of two years. I’m looking forward to seeing more of this. Lung cancer needs a Gleevec.

Next Previous link

Previous PostNext Post

Related Content

Blood Cancer OncTalk
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:

Forum Discussions

Hi Revtoby, Welcome to Grace.  I'm sorry you and your wife are worried about cancer but we couldn't say whether or not your wife's leison is cancer no matter how much...

Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...

Hello and welcome to Grace.  I'm sorry you're going through this worry.  It is normal to watch a small very slow-growing solid nodule with once-a-year CT scans.  Anything less than a...

Thanks you very much. So in summary the course of action taken suggested by lung specalist (re scan in 12 months) seems appropriate? And a PET at this stage is probably...

Recent Comments

Hi Mackensie,  I'm sorry…
By JanineT GRACE … on
Pencoast Tumor
By Mackensie31 on
Blue Sun, I'm glad your mom…
By JanineT GRACE … on
Good news
By happybluesun on